These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 1349308)

  • 21. Recurrent neuroleptic malignant syndrome due to tiapride and haloperidol: the possible role of D-2 dopamine receptors.
    Hermesh H; Huberman M; Radvan H; Kott E
    J Nerv Ment Dis; 1984 Nov; 172(11):692-5. PubMed ID: 6238132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The neuroleptic malignant syndrome--a review.
    Gibb WR; Lees AJ
    Q J Med; 1985 Aug; 56(220):421-9. PubMed ID: 2864716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of dopamine agonists and neuroleptic agents on striatal acetylcholine transmission in the rat: evidence against dopamine receptor multiplicity.
    Scatton B
    J Pharmacol Exp Ther; 1982 Jan; 220(1):197-202. PubMed ID: 6118430
    [No Abstract]   [Full Text] [Related]  

  • 24. [Neuroleptic malignant syndrome (dopamine-dependent malignant hyperthermia). 4 different cases].
    Truong DD; Sczesni B; Fahn S; Gross J; Donovan K; van Bakel A; Wiley MK
    Nervenarzt; 1988 Feb; 59(2):103-9. PubMed ID: 2896306
    [No Abstract]   [Full Text] [Related]  

  • 25. Clozapine-induced neuroleptic malignant syndrome: an interaction between dopaminergic and purinergic systems?
    Lara DR; Wolf AL; Lobato MI; Baroni G; Kapczinski F
    J Psychopharmacol; 1999; 13(3):318-9. PubMed ID: 10512095
    [No Abstract]   [Full Text] [Related]  

  • 26. Investigation of striatal dopamine D2 receptor acquisition following prenatal neuroleptic exposure.
    Schmidt MH; Lee T
    Psychiatry Res; 1991 Mar; 36(3):319-28. PubMed ID: 1676523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced injury of dopaminergic nigrostriatal system on movement components of the instrumental reflex and motor thalamic neurons' reactions in the cat.
    Voloshin MYa ; Zelenskaya VS; Lukhanina EP; Burchinskaya LF; Kolomietz BP; Nosenko ND
    Neuroscience; 1991; 45(2):291-305. PubMed ID: 1762681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Striatal dopamine D2 receptors in tardive dyskinesia: PET study.
    Blin J; Baron JC; Cambon H; Bonnet AM; Dubois B; Loc'h C; Mazière B; Agid Y
    J Neurol Neurosurg Psychiatry; 1989 Nov; 52(11):1248-52. PubMed ID: 2574230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of loading rate in neuroleptic malignant syndrome.
    Shalev A; Hermesh H; Munitz H
    Am J Psychiatry; 1986 Aug; 143(8):1059. PubMed ID: 2873750
    [No Abstract]   [Full Text] [Related]  

  • 30. Destruction of post-synaptic dopamine receptors prevents neuroleptic-induced activation of striatal tyrosine hydroxylase but not dopamine synthesis stimulation.
    Di Chiara G; Onali PL; Tissari AH; Porceddu ML; Morelli M; Gessa GL
    Life Sci; 1978 Aug; 23(7):691-6. PubMed ID: 29204
    [No Abstract]   [Full Text] [Related]  

  • 31. [Neuroleptic malignant syndrome].
    Sczesni B; Schröder J; Becker H; Przuntek H
    Wien Klin Wochenschr; 1991; 103(1):1-7. PubMed ID: 1673041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of chronic administration of neuroleptic and anticholinergic agents on densities of D2 dopamine and muscarinic cholinergic receptors in rat striatum.
    Boyson SJ; McGonigle P; Luthin GR; Wolfe BB; Molinoff PB
    J Pharmacol Exp Ther; 1988 Mar; 244(3):987-93. PubMed ID: 2908050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroleptic malignant syndrome.
    Gratz S; Simpson G
    Br J Psychiatry; 1990 Oct; 157():617-8. PubMed ID: 1983391
    [No Abstract]   [Full Text] [Related]  

  • 34. [Current theories on the role of dopamine in the mechanism of action of neuroleptic drugs].
    Płaźnik A; Kostowski W
    Psychiatr Pol; 1984; 18(1):39-47. PubMed ID: 6146150
    [No Abstract]   [Full Text] [Related]  

  • 35. Neuroleptic malignant syndrome.
    Murray JB
    J Gen Psychol; 1987 Jan; 114(1):39-46. PubMed ID: 2881974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. "Hit-and-run" actions at dopamine receptors, part 1: Mechanism of action of atypical antipsychotics.
    Stahl SM
    J Clin Psychiatry; 2001 Sep; 62(9):670-1. PubMed ID: 11681760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Malignant neuroleptic syndrome: a review].
    Cuesta Zorita MJ; Huete Muñoz T; Ojeda Ortega JV; Moreno Rodríguez L; Ortiz Manchado O; Conde López V
    Arch Neurobiol (Madr); 1986; 49(4):201-12. PubMed ID: 2875697
    [No Abstract]   [Full Text] [Related]  

  • 38. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs.
    Marsden CD; Jenner P
    Psychol Med; 1980 Feb; 10(1):55-72. PubMed ID: 6104342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physiology and pharmacology of dopamine D2-receptors: their implications in dopamine-substitute therapy for Parkinson's disease.
    Mercuri NB; Calabresi P; Bernardi G
    Neurology; 1989 Aug; 39(8):1106-8. PubMed ID: 2569697
    [No Abstract]   [Full Text] [Related]  

  • 40. Tardive dyskinesia: a role for the endogenous opioid system.
    Sandyk R
    Med Hypotheses; 1986 Jan; 19(1):71-4. PubMed ID: 2871480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.